Clinical Trials Directory

Trials / Completed

CompletedNCT01567501

Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition

A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Levocetirizine Dihydrochloride 5 mg Tablets With Xyzal® 5 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fed Condition

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
28 (actual)
Sponsor
IPCA Laboratories Ltd. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This is a single-dose, Randomized, two-period,cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in normal, healthy, adult, human subjects.

Detailed description

Primary Objective of this pivotal study was to assess the bioequivalence between Test Product: Levocetirizine Dihydrochloride 5 mg Tablets of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Xyzal® (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA, under fed condition in normal, healthy, adult, human subjects in a randomized crossover study. Secondary Objective was to monitor the safety and tolerability of a single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets in normal,healthy, adult, human subjects. The study was conducted with 28 healthy adult subjects. In each study period, a single 5 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position. The duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period.

Conditions

Interventions

TypeNameDescription
DRUGLevocetirizine Dihydrochloride tablets 5 mg5 mg tablet once in a day
DRUGLevocetirizine Dihydrochloride5 mg tablet once in a day

Timeline

Start date
2012-02-01
Primary completion
2012-03-01
Completion
2012-03-01
First posted
2012-03-30
Last updated
2012-12-03

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT01567501. Inclusion in this directory is not an endorsement.